State-of-the-art review of NAFLD treatments covering lifestyle interventions, pioglitazone, vitamin E, and emerging therapies including GLP-1 receptor agonists showing promise for the disease affecting 30% of adults.
30% prevalence, 0 drugsNAFLD affects nearly one-third of adults worldwide but has no approved pharmacotherapy — making it one of the biggest unmet treatment needs in medicine
What the researchers found
No approved NAFLD-specific pharmacotherapy. Current approaches: lifestyle modification, pioglitazone, vitamin E. Emerging: GLP-1RAs showing promise for liver fat reduction and inflammation. NAFLD affects ~30% of adults, up to 70% of T2DM patients.
Why it matters
NAFLD is becoming the leading cause of liver transplantation. GLP-1 drugs that address both diabetes and fatty liver could treat the root cause for millions of patients with overlapping conditions.
The numbers in context
30% prevalence; 70% in T2DM; candidates: pioglitazone, GLP-1RAs, SGLT2i, vitamin E, statins, FXR agonists
How the study worked
Narrative review of NAFLD treatment landscape covering epidemiology, pathogenesis, current therapies, and emerging pharmacological approaches.
Who was studied
N/A (review covering NAFLD population, ~30% of adults, ~70% of T2DM patients)
What this study cannot tell us
Review article. Most emerging drugs in early-to-mid clinical development. Long-term outcomes data limited. NAFLD heterogeneity makes one-size-fits-all treatment difficult.
How to read the evidence
Not applicable (state-of-the-art review). Based on clinical trial evidence for established and emerging therapies.
When this study was published
Published 2021. Semaglutide has since shown strong NASH trial results and resmetirom became the first approved NASH drug in 2024.
The bigger picture
The convergence of obesity, diabetes, and liver disease makes NAFLD one of the most important treatment targets of the decade. GLP-1 drugs' multi-organ benefits position them as leading candidates for this multi-system disease.
Questions still open
- Will semaglutide become the first approved drug specifically for NAFLD?
- Can combination approaches (GLP-1 + other agents) achieve liver fibrosis reversal?
- Should NAFLD screening be routine in diabetes patients?
Common questions
Is there a drug for fatty liver disease?
Can GLP-1 drugs help fatty liver?
Read the original research
Treatments for NAFLD: State of Art.
International journal of molecular sciences, 22(5)
Citation
Mantovani, Alessandro; Dalbeni, Andrea. (2021). Treatments for NAFLD: State of Art.. International journal of molecular sciences, 22(5). https://doi.org/10.3390/ijms22052350